RFC
TARA icon

Russell Frank Company’s Protara Therapeutics TARA Stock Holding History

Russell Frank Company’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-68
Closed -$48K – 3054
2015
Q2 		$48K Buy
+68
New +$42.1K ﹤0.01% 2964

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Russell Frank Company's TARA Position: Q3 2015 in Review

Russell Frank Company sold out of Protara Therapeutics (TARA) in Q3 2015, closing a stake of 68 shares — an estimated $48K sold.

Russell Frank Company first reported a position in TARA in Q2 2015 and held it in 1 quarter. The position peaked at $48K in Q2 2015. 44 funds tracked by Wall St. Rank hold TARA as of Q3 2015.

  • Russell Frank Company reported no remaining Protara Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Russell Frank Company sold 68 Protara Therapeutics shares in Q3 2015, an estimated $48K.
  • Russell Frank Company first reported a position in Protara Therapeutics in Q2 2015 and held it in 1 quarter.
  • Russell Frank Company's Protara Therapeutics position peaked at $48K in Q2 2015.
  • 44 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2015.

Based on Russell Frank Company's 13F filing for Q3 2015, filed 23 Oct 2015.